Linzagolix: an oral gonadotropin-releasing hormone receptor antagonist treatment for uterine fibroid-associated heavy menstrual bleeding

Gonadotropin-releasing hormone receptor antagonists, as selective gonadotropin-releasing hormone receptor blockers, reduce the release of follicle-stimulating hormone and luteinising hormone from the pituitary, resulting in anovulation and amenorrhea in a dose-dependent manner.1 The suppression of gonadotropin-releasing hormone receptor presents several potential therapeutic options for hormone-dependent disorders, such as endometriosis, uterine fibroids, prostatic hyperplasia, or prostate cancer.